AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$CBLL

Chao Xingjuan sold $522K of CBLL

Chao Xingjuan (President and CEO) sold 20,846 shares of Ceribell, Inc. (CBLL) at $25.03 ($0.52M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chao Xingjuan
Published Sep 18, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 1:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CBLL
Neutral
high confidence
Mentioned
$CBLL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBLLNeutralLow
01

Why it matters

The sale is modest and pre‑arranged, likely having negligible effect on CBLL's stock price.

02

Market read

Routine insider sale; low trading relevance.

03

What to watch

Potential tax planning or diversification motives behind the 10b5‑1 sale.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑09‑15

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$CBLLNeutralHigh confidence
Context

President & CEO Chao Xingjuan sold 20,846 shares for $521,775.38 via a 10b5‑1 plan on 2026‑09‑15.

Expected impact

Minimal short‑term impact; price likely unchanged unless cumulative insider sales increase.

Evidence & confidence

The transaction size (≈0.07% of holdings) is small and pre‑arranged, limiting market reaction.

Market effects

Sector

No broader sector impact; insider sales are company‑specific.

Regional

Limited to Ceribell shareholders; no regional effect.

Global

None

Counterpoint

What could challenge this read

If the CEO is cashing out, it could hint at upcoming challenges not yet public.

Key entities

  • Company
    Ceribell, Inc.

    Medical device company developing rapid diagnostic platforms.

  • Executive
    Chao Xingjuan

    President and CEO of Ceribell, filing insider sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CBLL insider trading history →

Related articles

OCT 2
$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

rttnews.com3 min
SEP 30
$CBLLMedAI 8/10

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Ceribell, Inc. (Nasdaq: CBLL) received FDA 510(k) clearance for new software for its EEG system, enabling easier interpretation of brain activity trends. The update includes Alpha-Delta Ratio, Burst Suppression, and Amplitude-Integrated EEG monitoring, applicable to patients of all ages. The company expects to roll out the features in the first half of 2027.

globenewswire.com2 min
AUG 10
$CBLLHigh

Ceribell Reports Second Quarter 2026 Financial Results

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor

SEC EDGAR 8-K6 min